Arrowhead Research (ARWR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Arrowhead Reports Fiscal 2016 Third Quarter Results
August 9, 2016 4:01 PM EDTConference Call and Webcast Today at 4:30 p.m. EDT
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at... More
Arrowhead Pharmaceuticals Prices $45 Million Private Offering
August 9, 2016 9:03 AM EDTPASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million. The offering was priced at $5.90 per share.
Cantor Fitzgerald & Co. acted as sole placement agent for the offering.
Approximately 7.63 million shares of common stock are expected to be issued at the closing of the offering. The offering is expected to close on or about August 12, 2016, subject to the satisfaction of customary closing conditions.
This press release shall not... More
